## Charlotte Proudhon

## List of Publications by Citations

Source: https://exaly.com/author-pdf/4621440/charlotte-proudhon-publications-by-citations.pdf

Version: 2024-04-05

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

967 28 15 23 h-index g-index citations papers 28 1,265 4.13 7.2 avg, IF L-index ext. papers ext. citations

#	Paper	IF	Citations
23	Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. <i>Journal of the National Cancer Institute</i> , <b>2018</b> , 110, 560-567	9.7	137
22	Circulating tumor cells: clinical validity and utility. <i>International Journal of Clinical Oncology</i> , <b>2017</b> , 22, 421-430	4.2	129
21	Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy.  Nature Reviews Clinical Oncology, 2018, 15, 639-650	19.4	108
20	Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. <i>Clinical Chemistry</i> , <b>2017</b> , 63, 691-699	5.5	104
19	Circulating tumor cells in breast cancer. <i>Molecular Oncology</i> , <b>2016</b> , 10, 418-30	7.9	99
18	Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer. <i>Molecular Oncology</i> , <b>2016</b> , 10, 481-93	7.9	61
17	Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial. <i>Cells</i> , <b>2019</b> , 8,	7.9	40
16	Circulating Tumor Cells in Early Breast Cancer. JNCI Cancer Spectrum, 2019, 3, pkz026	4.6	38
15	Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 5767-5771	12.9	38
14	Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 2109-2115	12.9	32
13	International Interlaboratory Digital PCR Study Demonstrating High Reproducibility for the Measurement of a Rare Sequence Variant. <i>Analytical Chemistry</i> , <b>2017</b> , 89, 1724-1733	7.8	31
12	Multiple Hotspot Mutations Scanning by Single Droplet Digital PCR. Clinical Chemistry, 2018, 64, 317-32	<b>8</b> 5.5	28
11	Microfluidic extraction and digital quantification of circulating cell-free DNA from serum. <i>Sensors and Actuators B: Chemical</i> , <b>2019</b> , 286, 533-539	8.5	24
10	High-Accuracy Determination of Microsatellite Instability Compatible with Liquid Biopsies. <i>Clinical Chemistry</i> , <b>2020</b> , 66, 606-613	5.5	16
9	A single droplet digital PCR for ESR1 activating mutations detection in plasma. <i>Oncogene</i> , <b>2020</b> , 39, 298	17 <sub>9</sub> 299	5 16
8	Limited Sensitivity of Circulating Tumor DNA Detection by Droplet Digital PCR in Non-Metastatic Operable Gastric Cancer Patients. <i>Cancers</i> , <b>2019</b> , 11,	6.6	14
7	PADA-1: A randomized, open label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with hormone therapy driven by circulating DNA ESR1 mutation monitoring in ER-positive, HER2-negative metastatic breast cancer patients <i>Journal of Clinical</i>	2.2	10

## LIST OF PUBLICATIONS

6	Circulating tumor DNA for triple-negative breast cancer diagnosis and treatment decisions. <i>Expert Review of Molecular Diagnostics</i> , <b>2016</b> , 16, 39-50	3.8	9	
5	Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients. <i>Breast Cancer Research</i> , <b>2021</b> , 23, 31	8.3	9	
4	Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer. <i>Npj Breast Cancer</i> , <b>2021</b> , 7, 115	7.8	9	
3	Shallow Whole-Genome Sequencing from Plasma Identifies FGFR1 Amplified Breast Cancers and Predicts Overall Survival. <i>Cancers</i> , <b>2020</b> , 12,	6.6	8	
2	Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions. <i>Journal of Visualized Experiments</i> , <b>2018</b> ,	1.6	3	
1	Abstract 3390: Predictive and prognostic value of circulating tumor DNA (ctDNA) compared to circulating tumor cells (CTC) in a prospective cohort of metastatic breast cancer patients: The UCBG COMET trial <b>2020</b> ,		2	